Alternative Therapies for Renal Cell Carcinoma

Systemic Treatment Options

• The European Society for Medical Oncology recommends interferon-alpha as a Level I-D evidence option for good or intermediate prognosis patients with clear cell renal cell carcinoma, but only when VEGF-targeted agents or immunotherapy combinations cannot be safely administered 1, 2
• Interleukin-2 is graded as Level III-C evidence and should be reserved for very selected cases only, due to its significant toxicity profile and low overall response rates 1, 2

Non-Systemic Alternative Approaches

• The European Association of Urology recommends active surveillance as an alternative to immediate intervention for patients ≥75 years with substantial comorbidities and solid renal tumors measuring <4 cm 4
• Ablative treatments, such as radiofrequency ablation, cryoablation, or microwave ablation, can serve as alternatives to surgery in elderly patients with small cortical tumors (≤3 cm) 4

Radiation-Based Alternatives

• Stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) can be considered for metastatic lesions after multidisciplinary review, particularly for brain metastases as an alternative to whole-brain radiotherapy 1, 2, 6
• Conventional radiotherapy has a limited role in primary renal cell carcinoma management but can serve as an alternative for unresectable local or recurrent disease 1, 2

Supportive Care Alternatives

• The European Society for Medical Oncology recommends zoledronic acid as a Level II-A evidence option to reduce skeletal-related events in patients with bone metastases 1, 2
• Corticosteroids can provide effective temporary relief of cerebral symptoms in patients with brain metastases and serve as an alternative to immediate radiation in select cases requiring symptom control 1, 2
• Best supportive care remains the only suitable treatment option for many poor-prognosis patients, prioritizing quality of life over potentially toxic systemic therapies with minimal expected benefit 1, 2